This week has seen Generics Bulletin publish its annual top 50 ranking of the leading companies in the off-patent sector.
Across three separate articles, we brought you the details of change among the top 10 companies; cast an eye over...
Generics Bulletin’s Top 50 Ranking For 2022
Compiling All The Data From Our List Of The Top Industry Players
Listen to this article
This article compiles all the data from Generics Bulletin’s 2022 ranking of the top 50 generics and biosimilars companies, including additional details of how the financial figures stack up.
Stay ahead of every shift in generics and biosimilars.
More from Company Rankings
• By
This article compiles all of the data from Generics Bulletin’s 2024 ranking of the Top 50 firms across the generics and biosimilars industry, including additional details of how the various financial figures stack up.
• By
In the third instalment of this year’s Generics Bulletin Top 50, we look at some of the firms that have been eliminated from the bottom of our table as others have entered the picture.
• By
In the second part of Generics Bulletin’s Top 50, we see some companies rising up the rankings of generics and biosimilars players worldwide, passing others that are moving in the opposite direction.
More from Market Intelligence
• By
Polpharma has struck a deal with MSN Laboratories that will see the Polish generics player distribute the Indian firm’s hospital portfolio in Poland.
• By
Following the FDA’s approval of A 150mg version of Accord’ Herceptin biosimilar, the US agency has now greenlit a higher 400mg strength version of the rival.